Journal Title：Translational Cancer Research

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

Translational Cancer Research（Transl Cancer Res TCR；印刷版 ISSN：2218-676X；在线 ISSN 2219-6803；http://tcr.amegroups.com/）是一本开放获取、同行评审期刊，被 Science Citation 收录扩展指数 (SCIE)。 TCR 发表新治疗干预的实验室研究以及评估癌症新治疗模式的临床试验；将实验室和临床环境联系起来的新型研究调查的结果，包括风险评估、细胞和分子表征、预防、检测、诊断和治疗人类癌症，总体目标是改善癌症患者的临床护理。 TCR 的重点是原创的、经过同行评审的、以科学为基础的研究，成功地将临床医学推向提高患者生活质量的目标。编辑和一个由科学家和临床医生科学家以及其他专家组成的国际咨询小组将按照高质量标准持有 TCR 文章。我们接受原创文章以及评论文章、社论和简短文章。